Basic Information
Yselty
Regulatory Information
EMEA/H/C/005442
June 14, 2022
December 16, 2021
5
March 12, 2025
Company Information
Ireland
3rd Floor, Kilmore House Park Lane, Spencer Dock Dublin 1, D01 YE64
Theramex Ireland Ltd.
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Yselty is indicated in adult women of reproductive age for: - treatment of moderate to severe symptoms of uterine fibroids, - symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis (see section 5.1).
Overview Summary
Yselty is a medicine used in adult women of childbearing age to treat: - moderate to severe symptoms of uterine fibroids, which are non-cancerous (benign) tumours of the womb (uterus); - symptoms of endometriosis, a condition where tissue similar to the endometrium (the lining of the womb) grows outside the womb. It is used in women who have already had treatment for this condition. Yselty contains the active substance linzagolix choline.